论文部分内容阅读
目的 :观察瘤内注射 MAA和 3 2 P胶体治疗不能手术肝癌的有效性和毒副作用。 方法 :B超引导下瘤内注射 MAA和 3 2 P胶体治疗 30例原发性肝癌 ( PHC) ,观察治疗前后病人的临床表现、组织病理学、彩色多普勒超声、病灶体积变化、血清 AFP水平以及肝肾功能、血常规和免疫指标。 结果 :治疗后 ,96.7% PHC临床症状减轻 ,血清 AFP水平明显下降 ;肿块缩小率≥ 50 %者占 75.6% ,平均肿块缩小率53.3% ,彩色多普勒显示 81 .9%的肿块血供减少或消失。 2 0例组织学检查发现治疗区内肿瘤组织出现完全或部分坏死、纤维化。 30例 PHC6个月、1年、2年、3年生存率分别为 1 0 0 %、90 %、76.7%、43.3% ,平均生存期 1 9.5月。局部无并发症 ,治疗前后 ECG、肝肾功能、血常规和免疫功能均无变化。结论 :超声引导下经皮肝穿瘤内注射 MAA和3 2 P胶体对不能手术的 PHC是一种简单、安全和有效的新方法 ,副作用低 ,适应证广。
Objective : To observe the efficacy and toxic side effects of intratumoral injection of MAA and 3 2 P colloids in the treatment of unresectable liver cancer. METHODS: Intratumoral injection of MAA and 3 2 P colloids were used to treat 30 cases of primary liver cancer (PHC) under ultrasound guidance. The clinical manifestations, histopathology, color Doppler ultrasonography, lesion volume changes, and serum AFP were observed before and after treatment. Levels as well as liver and kidney function, blood routine and immune indicators. Results: After treatment, the clinical symptoms of 96.7% PHC were relieved and the serum AFP level was significantly decreased; the tumor shrinkage rate was ≥ 50% accounted for 75.6%, the average tumor shrinkage rate was 53.3%, and color Doppler showed 81.9% of the tumor blood supply was reduced. Or disappear. Twenty cases of histological examination revealed complete or partial necrosis and fibrosis of the tumor tissue in the treated area. The survival rates of 30 PHC patients at 6 months, 1 year, 2 years, and 3 years were 100%, 90%, 76.7%, and 43.3%, respectively, and the average survival time was 19.5 months. Locally without complications, there was no change in ECG, liver and kidney function, blood routine, and immune function before and after treatment. Conclusion : Ultrasound-guided percutaneous intrahepatic injection of MAA and 3 2 P colloids is a simple, safe and effective method for inoperable PHC with low side effects and wide indications.